CompletedPhase 1NCT01952444
Safety, Tolerability and PK of Intravenous (IV) ETI-204 Alone and in Presence of Ciprofloxacin in Adult Volunteers
Studying Inhalational anthrax
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Elusys Therapeutics
- Principal Investigator
- David Mathews, MD, mdQuintiles, Inc.
- Intervention
- ETI-204(biological)
- Enrollment
- 40 target
- Eligibility
- 18-60 years · All sexes
- Timeline
- 2013 – 2014
Study locations (1)
- Quintiles, Overland Park, Kansas, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01952444 on ClinicalTrials.gov